Your buyer is not “the therapy market”: how to map channels before entering Germany

Why a supplier needs a buyer/channel map before an event

For a B2B supplier entering Germany’s therapy and rehabilitation sector, the first temptation is to define the market by the people who use the product: therapists, clinics or rehabilitation professionals. That is usually too coarse for a commercial decision. The same product can have a user, an economic buyer, an institutional approver, an infrastructure dependency and an influence channel that are not the same actor.

The public evidence around therapie HAMBURG points to a much more fragmented commercial system. The event itself spans therapy and rehabilitation equipment, practice organization, digital administration, services, training and professional education. Its visitor groups include several therapeutic professions as well as physicians and clinic management. That is useful evidence of market heterogeneity — but it is still an event sampling frame, not a census of German demand.

The practical question is therefore not “Who buys therapy technology?” It is: for a specific product, who uses it, who pays or approves, which institution owns the workflow, which infrastructure or reimbursement context shapes adoption, which actors influence trust or access, and which channel can actually get a supplier into the account? The useful artifact is a buyer/channel map, not a sector label.

1. Outpatient therapy practices are a distinct buyer universe

Germany’s GKV-Spitzenverband maintains a Heilmittelerbringerliste for authorized outpatient practices in physiotherapy, occupational therapy, podiatry, nutrition therapy and speech-related therapy. The important structural detail is what the list does not contain: hospitals, rehabilitation institutions and comparable facilities are explicitly outside this register.

That immediately tells a supplier something useful. “Therapy providers” are not one account universe. An outpatient practice can be a small owner-led business, a larger therapy center or a multi-site operator, but it sits in a different institutional and purchasing context from a rehabilitation clinic or hospital department.

The national GKV contracts for disciplines such as physiotherapy and occupational therapy also show that service provision is embedded in defined contractual and reimbursement structures. A supplier does not need to become a reimbursement adviser to notice the commercial implication: workflow, documentation, billing, practice organization and compliance-adjacent requirements can shape willingness to adopt technology just as much as a product feature.

Observed: there is a nationally defined universe of authorized outpatient providers with discipline-specific contractual frameworks. Commercial implication: independent practices deserve their own account model and discovery questions. What this cannot prove: the number of economically attractive accounts for a given product, their budget, buying cycle or willingness to switch.

Field question: for the supplier’s specific product, who is the economic buyer inside an outpatient practice — owner, practice manager, clinical lead, IT/service partner or another role — and what workflow problem is painful enough to trigger a purchase?

2. Clinics and rehabilitation facilities are not just larger practices

Hospitals and rehabilitation institutions are absent from the GKV outpatient provider list for a reason: they belong to different organizational settings. Deutsche Rentenversicherung’s rehabilitation statistics make the distinction visible at scale. In the Reha-Bericht 2025, most adult medical rehabilitation services remain inpatient, while ambulatory rehabilitation is a distinct and growing mode.

For a technology supplier, that is not a market-size estimate. It is a warning against copying an outpatient practice sales motion into a rehabilitation facility. A clinic or rehab provider can have different procurement, governance, security, integration, budgeting and stakeholder structures. The user of a device or software may have little authority over the purchase.

Observed: rehabilitation activity spans distinct inpatient and outpatient settings. Commercial implication: clinic/rehab accounts need their own stakeholder and procurement map. What this cannot prove: which facilities need a particular technology, how procurement is organized in every institution or whether centralized purchasing is decisive in a specific segment.

Field question: when the end user is a therapist but the account is a rehabilitation institution, who owns the budget, who validates workflow fit, who controls IT/security and who can block adoption?

3. Heilmittel and Hilfsmittel sit next to each other — but they are not the same channel

The therapy and rehabilitation ecosystem also contains suppliers of assistive and rehabilitation products. gematik treats Heilmittelerbringende and Hilfsmittelerbringende as separate provider groups when it explains access to the Telematikinfrastruktur. For Hilfsmittel, the examples include medical supply stores, orthopaedic and rehabilitation technology, hearing care and homecare.

This distinction matters commercially because the path to the end user can change. A therapy practice may be the place where a need becomes visible or a product is recommended, while the purchasing, provision, approval or servicing channel may sit elsewhere. Conversely, a device bought directly by a practice follows a different route from a patient-specific assistive product supplied through a specialized provider.

Observed: the official digital-health infrastructure distinguishes therapy-service providers from assistive-product providers. Commercial implication: a supplier should map user, recommender, buyer, provider and payer/infrastructure roles separately instead of assuming they collapse into one customer. What this cannot prove: the legally correct pathway for any specific device or product — that requires product-specific regulatory and reimbursement analysis outside the scope of this market map.

Field question: is the supplier selling to a practice, through a specialist provider, into an institution, or into a workflow where several of those actors must align?

4. Digital infrastructure creates a separate buying conversation

For therapy practices, digitalization is not an abstract theme. gematik provides a dedicated TI pathway for Heilmittelerbringende, including secure communication, electronic health data exchange and financing arrangements for connection. The event floor reflects that operational layer: therapie HAMBURG lists digital organization and administration as a product category, and current exhibitors include companies presenting practice software, billing, cloud workflows, digital identity and TI access.

Two examples illustrate the breadth without proving demand. Bundesdruckerei is using the event to present digital identity and secure TI access for therapy providers. opta data and thevea are presenting practice software, billing and TI integration. The start-up area also includes digital tools aimed at front-desk and practice workflow problems.

Observed: practice IT, administration and health-system connectivity are visible commercial categories around the event. Commercial implication: for digital suppliers, the buying problem may be less “healthcare innovation” and more workflow replacement, interoperability, administrative burden, security and implementation friction. What this cannot prove: adoption rates, customer satisfaction, vendor quality or the relative size of each software category.

Field question: which workflow is the buyer actually paying to change — scheduling, documentation, billing, communication, identity/security, reporting or patient interaction — and what must the product integrate with before the buyer will consider switching?

5. Professional associations, education and events are influence channels — not necessarily buyers

therapie HAMBURG combines a trade fair with certified continuing education, workshops and professional exchange. Professional associations participate alongside commercial exhibitors, and the event also surfaces business topics such as practice development. That makes the fair useful for understanding how information and trust move through the professional community.

But influence is not the same as procurement. A professional association may shape awareness, standards, education or access to a community without buying the supplier’s product. A training provider may influence practice behavior but have no role in capital purchasing. A congress speaker may identify a real problem without representing budget authority.

Observed: professional education, associations and commercial suppliers coexist in the same field environment. Commercial implication: channel mapping should separate credibility and discovery partners from transaction partners. What this cannot prove: that any association endorses a product or that event visibility converts into sales.

Field question: which organizations can credibly open access to a buyer segment, which can validate a problem, and which can actually participate in a commercial transaction?

6. What therapie HAMBURG is useful for

The current event is a strong field surface because its product taxonomy spans equipment, rehabilitation aids, physical and physiotherapy devices, occupational and speech-therapy equipment, digital administration, services, training and other practice-facing categories. The organizer expects more than 200 exhibitors, while the visitor framing spans therapeutic professions and clinic management.

That density makes the event useful for comparing channel hypotheses quickly. A supplier can test whether the same problem is described differently by a practice owner, therapist, clinic manager, software vendor, association or equipment provider. It can also reveal categories the desk map missed.

But the fair cannot tell us the whole market. Exhibitors are self-selected participants. Visitor conversations are not a representative demand survey. Start-up presence does not prove adoption. A busy stand does not establish buyer intent. An association’s presence does not imply endorsement.

The right use of the event is therefore validation, not enumeration: take a structured buyer/channel hypothesis into the room, then record where real conversations confirm, split or contradict it.

A practical buyer/channel map to test

Outpatient Heilmittel practice — likely questions: owner-led buying, workflow pain, documentation and administration, staff time, implementation burden, equipment utilization, financing and switching triggers.

Clinic or rehabilitation facility — likely questions: procurement process, department vs central budget, IT/security, integration, clinical operations, service/support and multi-stakeholder approval.

Hilfsmittel / rehabilitation technology channel — likely questions: who supplies, fits, services or reimburses the product; whether the therapy provider is buyer, recommender or user; and where product-specific regulation changes the route.

Digital / practice infrastructure supplier — likely questions: installed systems, TI connectivity, billing/documentation workflow, data migration, security, interoperability and recurring support.

Professional association / education / network — likely questions: recurring member problems, information channels, accepted terminology, professional priorities and credible routes to reach decision-makers.

Event / distributor / partner layer — likely questions: which actors aggregate fragmented accounts, which already serve the target workflow, and where a partnership may be more efficient than direct selling.

Questions worth taking into the hall

Who uses the product, who approves it, who pays for it and who can stop the purchase?

Which account type has the problem most often: independent practice, larger therapy center, rehab facility, hospital department, specialist provider or another setting?

What must already be true in the buyer’s workflow — digital infrastructure, documentation process, physical space, training, integration or reimbursement pathway — before adoption is realistic?

Is the supplier solving a clinical problem, an operational problem, an administrative problem or an infrastructure problem? Those are different buying conversations even when the same therapist uses the product.

Does the market require direct account acquisition, a distributor, a software/infrastructure partner, an association relationship or several channels in parallel?

Which event-visible actors are important because they buy, and which are important because they influence, integrate, refer, regulate or provide access?

What this map does not do

This is not medical advice, a clinical evaluation, a regulatory assessment or reimbursement guidance. It does not rank therapy products, assess treatment efficacy, estimate the size of the German therapy market or claim that a company visible at the event has buyer demand.

Its job is narrower and more useful for an entering B2B supplier: turn a vague sector label into a decision map of account types, user and buyer roles, workflow dependencies, influence channels and unanswered questions that can be tested with real counterparties.

The decision-useful output

A supplier preparing for therapie HAMBURG should not leave desk research with one list called “therapy buyers.” The better artifact is a channel map with separate rows for user, economic buyer, institution, infrastructure dependency, influence channel and unanswered question — and a clear reason why each meeting could change the map.

That structure changes how meetings are selected. It prevents a product conversation with a therapist from being mistaken for procurement evidence. It distinguishes a clinic from an owner-led practice, a Hilfsmittel pathway from a Heilmittel workflow, and a professional influence channel from a sales channel. Most importantly, it gives the event a job: not to prove the market, but to improve the map.